Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
European Heart Journal|March 7, 2014
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trialsEvan A Stein, Robert P Giugliano, Michael J Koren, et al.The New England Journal of Medicine|April 1, 2014
A 52-week placebo-controlled trial of evolocumab in hyperlipidemiaDirk J Blom, Tomas Hala, Michael Bolognese, et al.Hypertension (Dallas, Tex. : 1979)|March 15, 2021
Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney DiseaseDominique M Bovée, Liwei Ren, Estrellita Uijl, et al.Journal of the American College of Cardiology|March 26, 2016
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF StudyJohn R Teerlink, G Michael Felker, John J V McMurray, et al.Diabetes|July 29, 2006
Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant statesYun S Lee, Woo S Kim, Kang H Kim, et al.JACC. Heart Failure|June 16, 2014
Charting a roadmap for heart failure biomarker studiesTariq Ahmad, Mona Fiuzat, Michael J Pencina, et al.The New England Journal of Medicine|February 7, 2019
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent PorphyriaEliane Sardh, Pauline Harper, Manisha Balwani, et al.The Journal of Clinical Investigation|September 3, 2010
Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-βPolakit Teekakirikul, Seda Eminaga, Okan Toka, et al.Journal of Hepatology|June 8, 2023
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trialsEd Gane, Young-Suk Lim, Jae B Kim, et al.The New England Journal of Medicine|June 11, 2020
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent PorphyriaManisha Balwani, Eliane Sardh, Paolo Ventura, et al.Pageof 3